Decoy Therapeutics director granted 3,000 restricted shares

A Decoy Therapeutics director received 3,000 restricted shares as equity compensation, vesting in full on August 30, 2027.

Rhea-AI Filing Summary

Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. HANISH ARNOLD C reported acquisition or exercise transactions in this Form 4 filing.

Decoy Therapeutics Inc. (DCOY) reported that director Arnold C. Hanish received a grant of 3,000 shares of restricted common stock on August 31, 2026 under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. The restricted stock will vest 100 percent on August 30, 2027. Following this award, Hanish beneficially owns 3,418 common shares, adjusted to reflect the reverse stock split effective on March 6, 2026. No Rule 10b5-1 trading plan is reported for this award.

Insider Trade Summary

Grant/Award: 3,000 shares

Grant/Award 1 txn

Insider HANISH ARNOLD C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	3,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 3,418 shares (Direct)

Footnotes (2)

1. F1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
2. F2. Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.

Key Figures

Restricted stock granted: 3,000 shares Vesting date: August 30, 2027 Shares beneficially owned after transaction: 3,418 shares +2 more

5 metrics

Restricted stock granted 3,000 shares Equity award to director Arnold C. Hanish on August 31, 2026

Vesting date August 30, 2027 Date when 100 percent of the restricted stock will vest

Shares beneficially owned after transaction 3,418 shares Director Arnold C. Hanish’s holdings after the grant, reverse-split adjusted

Transaction price per share $0.00 Equity award granted without cash consideration

Reverse stock split effective date March 6, 2026 Date used to adjust post-transaction beneficial ownership

Key Terms

Restricted stock, Equity Incentive Plan, reverse stock split

3 terms

Restricted stock financial

"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Equity Incentive Plan financial

"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

reverse stock split financial

"adjusted to reflect the reverse stock split effective on March 6, 2026"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

What insider transaction did Decoy Therapeutics (DCOY) report for Arnold C. Hanish?

Decoy Therapeutics reported that director Arnold C. Hanish received a grant of 3,000 shares of restricted common stock on August 31, 2026 as an equity award under the 2026 Equity Incentive Plan.

What are the vesting terms of the 3,000 restricted shares at DCOY?

The 3,000 restricted shares of Decoy Therapeutics common stock granted to Arnold C. Hanish will vest 100 percent on August 30, 2027, according to the grant footnote.

How many Decoy Therapeutics (DCOY) shares does Arnold C. Hanish own after this grant?

After the August 31, 2026 grant, Arnold C. Hanish beneficially owns 3,418 shares of Decoy Therapeutics common stock, with this amount adjusted to reflect the company’s reverse stock split effective on March 6, 2026.

Was the Decoy Therapeutics (DCOY) restricted stock grant made under a Rule 10b5-1 plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported in connection with this restricted stock grant to Arnold C. Hanish.

What plan governs the 3,000-share restricted stock award at Decoy Therapeutics (DCOY)?

The 3,000-share restricted stock award to Arnold C. Hanish was granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, as stated in the footnote to the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 05:45 PM Accepted by SEC EDGAR 09/02/2026 - 05:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HANISH ARNOLD C

(Last) (First) (Middle)

2450 HOLCOMBE BLVD STE X

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Decoy Therapeutics Inc. [ DCOY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A(1)		3,000	A	$0	3,418(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

2. Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.

	/s/Mark Rosenblum, as Attorney -in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)